Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat Alfa for ACE-I-Induced Angioedema
NCT06679426Phase 3Not yet recruiting
- Sponsor
- University of Cincinnati
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial comparing Conestat Alfa with Placebo (2 arms). Primary endpoint: Time to Onset of Symptom Relief at 24 hours. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
conestat alfa
Beyond the preview
Go deeper on NCT06679426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679426.